Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID
Claire Booth1,2, H Bobby Gaspar1,21Centre for Immunodeficiency, Molecular Immunology Unit, UCL Institute of Child Health, London, UK; 2Dept of Clinical Immunology, Great Ormond Street Hospital NHS Trust, London, UKAbstract: Adenosine deaminase deficiency (ADA) is a rare, inherited disorder of purine...
Enregistré dans:
Auteurs principaux: | Claire Booth, H Bobby Gaspar |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2009
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/951c4df78fd143a5b421a262ed2ac31b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy
par: Federico A. Moretti, et autres
Publié: (2021) -
Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency
par: Claudia A Montiel-Equihua, et autres
Publié: (2009) -
CRISPR/Cas9-Mediated Deletion of Foxn1 in NOD/SCID/IL2rg−/− Mice Results in Severe Immunodeficiency
par: Xinru Wei, et autres
Publié: (2017) -
Evaluation of ADA activity as a potential marker of disease severity in psoriasis patients
par: Khan SA, et autres
Publié: (2018) - Ada user journal